×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains
MarketWatch
Shares of Incyte Corp. inched 0.54% higher to $54.37 Tuesday, on what proved to be an all-around positive trading session for the stock...
1 day ago
Incyte Inks $750M Deal to Buy Escient and Skin Disease Drug Candidates
BioSpace
Published: Apr 23, 2024 By Nick Paul Taylor. Incyte_iStock, Bo Shen. Pictured: Incyte building in Wilmington, Delaware/iStock, Bo Shen.
2 weeks ago
Leo Pharma prepares to come for the topical JAK market as Incyte's Opzelura cream launch cools off
Fierce Pharma
Watch out, Incyte. Leo Pharma and its JAK inhibitor cream delgocitinib are coming to disrupt the topical atopic dermatitis market,...
5 days ago
We Think That There Are Issues Underlying Incyte's (NASDAQ:INCY) Earnings
Simply Wall Street
Despite posting some strong earnings, the market for Incyte Corporation's ( NASDAQ:INCY ) stock hasn't moved much. Our...
1 day ago
Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M
Fierce Biotech
Incyte is dolloping another deal onto its 2024 partnership plate, buying San Diego-based Escient Therapeutics for $750 million.
2 weeks ago
Incyte First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Yahoo Finance
Incyte ( NASDAQ:INCY ) First Quarter 2024 Results Key Financial Results Revenue: US$880.9m (up 8.9% from 1Q 2023). Net...
4 days ago
Incyte signs deal to acquire Escient Pharmaceuticals
Pharmaceutical Technology
Incyte has agreed to acquire US-based Escient Pharmaceuticals and its assets including two first-in-class small molecule antagonists...
2 weeks ago
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
Business Wire
WILMINGTON, Del. & SAN DIEGO--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) and Escient Pharmaceuticals, a clinical-stage drug discovery and...
2 weeks ago
Incyte Corp. stock rises Monday, still underperforms market
MarketWatch
Shares of Incyte Corp. inched 0.60% higher to $54.08 Monday, on what proved to be an all-around favorable trading session for the stock...
2 days ago
Incyte Jakafi Positive in Pooled Analysis of Five-Year Data
Yahoo News Singapore
Incyte (INCY) announced pooled analysis of five-year data from two phase III studies on Jakafi, which support previous long-term results.
3 days ago